May 24, 2023

Coverage of David Barr’s Arrival at Venable

2 min

The arrival of David Barr at Venable was covered by Law360, Attorney at Law, Bloomberg Law, and CityBiz on May 19, 2023, and Reuters on May 22, 2023. Mr. Barr joins the firm as a partner in the IP Litigation – Life Sciences Group in the New York office. He focuses on patent litigation, adversarial patent office proceedings, transactions, and counseling for life sciences clients.

Mr. Barr has litigated and tried patent cases in the federal district courts before both the bench and juries in matters involving small-molecule chemistry, therapeutic antibodies, cell and gene therapies, diagnostics, and medical devices, including Hatch-Waxman and biologics litigation, and has represented clients before the Court of Appeals for the Federal Circuit and the U.S. Supreme Court. He frequently coordinates with his clients’ foreign patent counsel when their matters have international scope and regularly advises on and litigates trade secret issues for his life sciences clients. Mr. Barr also has extensive experience in life sciences transactions, including mergers and acquisitions, asset purchases, and licensing and collaboration agreements. He is known for bringing to bear his deep patent litigation experience and knowledge of FDA regulatory issues in analyzing complex life sciences transactions, both in due diligence and in drafting patent licenses and related agreements. Mr. Barr is also a co-author and co-editor of the Practicing Law Institute (PLI) treatise Pharmaceutical and Biotech Patent Law and co-chairs an annual program for PLI on Developments in Pharmaceutical and Biotech Patent Law.

Commenting on his move to Venable, Mr. Barr said, “Venable has a deep bench of scientifically trained patent lawyers who clients want on their team. I am looking forward to joining and working with this vibrant group of highly accomplished patent lawyers and continuing to grow my practice.”